Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase (ALT) and Type 2 diabetes?: the Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit

M Yadagiri¹, P Sen Gupta¹, JW Stephens², A Robinson³, M Phylactou⁴, A Kennedy⁵, J Clarke⁶, J Wilding⁷, I W Gallen⁸, KA Adamson⁹, REJ Ryder¹, the ABCD nationwide dapagliflozin audit contributors¹⁰

HbA1c, weight, body mass index (BMI) and systolic blood pressure changes in the Association of British Clinical Diabetologists(ABCD) nationwide dapagliflozin audit Baseline Characteristics HbA1c Response to Dapagliflozin Weight & BMI Response to Dapagliflozin HbA1c and Weight Data HbA1c and Weight Data Systolic Blood Pressure Response to Dapagliflozin

Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase (ALT) and Type 2 diabetes?: the Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit

M Yadagiri¹, P Sen Gupta¹, SC Bain², A Robinson³, M Phylactou⁴, A Kennedy⁵, KA Adamson⁶, REJ Ryder¹

¹Sandwell and West Birmingham Hospitals NHS Trust, Birmingham

²Abertawe Bro Morgannwg University NHS Trust, Swansea/Neath

The Glycaemic Response to Dapagliflozin according to Intensity of Background Diabetes Treatment or Duration of Type 2 Diabetes: the Association of British Clinical Diabetologists Nationwide Dapagliflozin Audit

Ken Yan Thong, Yadagiri M, Sen Gupta P, Winocour P, Joshi M, Wilding J, Stephens JW, Bain SC, Robinson A, Gallen IW, Adamson KA, Ryder REJ

University of Western Australia

Sandwell and West Birmingham NHS Trust

East & North Hertfordshire NHS Trust

Guy's and St Thomas NHS Trust

Aintree University NHS Trust

Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase and Type 2 diabetes?: the Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit

M Yadagiri¹, P Sen Gupta¹, SC Bain², A Robinson³, K Darzy⁴, A Kennedy⁵, KA Adamson⁶, REJ Ryder¹

¹Sandwell and West Birmingham Hospitals NHS Trust, Birmingham

²Abertawe Bro Morgannwg University NHS Trust, Swansea/Neath

HbA1c, weight, body mass index (BMI) and systolic blood pressure changes in the ABCD nationwide dapagliflozin audit

M Yadagiri¹, P Sen Gupta¹, ML Cull¹, R Peter², P De¹, A Robinson³, KA Adamson⁴, REJ Ryder¹ on behalf of the ABCD nationwide dapagliflozin audit contributors

¹Sandwell and West Birmingham Hospitals NHS Trust, Birmingham

²Abertawe Bro Morgannwg University NHS Trust, Swansea/Neath

Dapagliflozin in renal impairment: Association of British Clinical Diabetologists (ABCD) Nationwide Dapagliflozin Audit

M Yadagiri, S Bain, T Robinson, JP Wilding, T Pang, B Mcgowan, P Winocour, V Oguntolu, J Clarke, H Partridge, IW Gallen, K Adamson, REJ Ryder On behalf of the ABCD nationwide dapagliflozin audit contributors

Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase (ALT) and Type 2 diabetes? Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit

Mahender Yadagiri ABCD Research Fellow P Sen Gupta, JW Stephens, A Robinson, M Phylactou, A Kennedy, J Clarke , J Wilding, IW Gallen, K A Adamson, R E J Ryder On behalf of the ABCD nationwide dapagliflozin audit contributors

HbA1c, weight, body mass index (BMI) and systolic blood pressure changes in the Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit 

Mahender Yadagiri ABCD Research Fellow ST5 Diab & Endo P Sen Gupta, M L Cull, R Peter, P De, A Robinson, KA Adamson, REJ Ryder on behalf of the ABCD nationwide dapagliflozin audit contributors

Clinical risk factors predicting genital fungal infections with sodium–glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit